Navigation Links
Biocept, Inc. Announces New Director Appointment - September 28, 2010
Date:10/7/2010

SAN DIEGO, Oct. 7 /PRNewswire/ -- Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced today the appointment of Bruce E. Gerhardt as Director.

"We are pleased to welcome Bruce to our Board. His experience will be invaluable to us as we move into our next stage of development," said Stephen M. Coutts, President and CEO.

Mr. Gerhardt has been a practicing Certified Public Accountant since 1986.  He is also a tax and business advisor providing tax compliance for small businesses and upper income individuals.  He earned his Bachelor of Arts Degree from the University of Southern California in 1973 and is a member of the American Institute of Certified Public

About Biocept

Biocept, an emerging biotechnology leader in cell separation technology, is developing novel diagnostic assays for personalized medicine in detection and monitoring of recurrent cancer. The CEE(TM) Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics to enable earlier, accurate and less invasive diagnoses. Isolation, purification and genetic analysis of rare cells, such as circulating tumor cells, are managed within our state-of-the-art CLIA-accredited laboratory. The clinical laboratory is accredited by the College of American Pathologists (CAP) and holds licenses in California and several other states.

Visit: http://www.biocept.com/


'/>"/>
SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biocept, Inc. Announces Two New Director Appointments
2. Biocept, Inc. Announces CEO and Director Appointments
3. GeneWize Announces New Skin Clearing Product and Teen Nutrition at Annual Convention
4. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
5. GeneGo Announces Integration With GenomeQuest for Pathway Analysis of Next Generation Sequencing Data
6. Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
7. Aeterna Zentaris Announces Orphan Drug AEZS-130 (Macimorelin, Solorel(TM)) Interim Phase 3 Data Analysis Shows Potential for 2011 Filing as Oral Diagnostic Test for Adult Growth Hormone Deficiency (AGHD)
8. Jazz Pharmaceuticals Announces Paragraph IV ANDA Filing for Xyrem
9. Ground Zero Pharmaceuticals Announces Expansion of Global Consulting in Somatic Cell Therapies
10. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
11. Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 18, 2017 The global biotechnology services ... billion by 2025, according to a new report ... been adaptive of the function of outsourcing certain ... Among the services outsourced, clinical trial management and ... & Johnson was the first pharmaceutical company to ...
(Date:1/18/2017)... January 18, 2017 According to a new market research ... Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) ... reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, growing ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports Medicine ... Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long Island ... anterior cervical discectomy and fusion on a 42 year old female who was ...
(Date:1/18/2017)... PRUSSIA, PA (PRWEB) , ... January 18, 2017 ... ... clinical operations again at the CHI SCOPE Summit for Clinical Ops Executives (Hyatt ... in engaging panel discussions to examine vital clinical research issues such as trial ...
Breaking Biology Technology:
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  CES ... performance biometric sensor technology, today announced the launch ... sensor systems, the highly-accurate biometric sensor modules ... biometric technology, experience and expertise. The two ... Benchmark designed specifically for hearables, and Benchmark BW2.0, ...
Breaking Biology News(10 mins):